The phase 2b VISUALIZE trial found abenacianine identified a clinically significant event in 45% of lung cancer surgeries, says Gavin M. Wright, MBBS, FRACS, PhD.
Gavin M. Wright, MBBS, FRACS, PhD
Advertisement
Articles by Gavin M. Wright, MBBS, FRACS, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Type C Meeting Supports Phase 3 Design for DLL3-Targeted ADC in ES-SCLC
2
FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
3
Zanidatamab/Chemo Achieves OS Benefit in HER2+ Gastroesopheageal Cancer
4
FDA Approval Sought for Selinexor Plus Ruxolitinib in Myelofibrosis
5